Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeting leukemia-initiating cells through pharmacologic inhibition of Pol I transcription to treat MLL-driven acute myeloid leukemia

ABSTRACT: Transcriptome analysis revealed differential responses to Pol I inhibition in p53WT and p53null AML in vivo

ORGANISM(S): Mus musculus

PROVIDER: GSE71531 | GEO | 2017/07/31

SECONDARY ACCESSION(S): PRJNA291442

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Project description: Not available

| S-EPMC4415852 | biostudies-literature

Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia.

Project description: Not available

| S-EPMC4319237 | biostudies-literature

MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity.

Project description: Not available

| S-EPMC5959866 | biostudies-literature

APR-246 enhances colorectal cancer sensitivity to radiotherapy

Project description:p53 mutation is common and highly related to radiotherapy resistance in rectal cancer. APR-246, as a small molecule, can restore the tumor-suppressor function to mutant p53. There is no study on combining APR-246 with radiation in rectal cancer; therefore, we examined whether APR-246 sensitized colorectal cancer cells with different p53 status to radiation. The combination treatment had synergistic effects on HCT116p53-R248W/-(p53Mut) cells, followed by HCT116p53+/+(p53WT) cells, and exhibited an additive effect on HCT116p53-/-(p53Null) cells through inhibiting proliferation, enhancing reactive oxygen species, and apoptosis. The results were confirmed in zebrafish xenografts. Comparison of the transcriptome in colorectal cancer cells with different p53 status 72hrs post-treatment with APR-246, irradiation, or the combination of APR-246 with irradiation was carried out. p53Mut and p53WT cells shared more activated pathways and differentially expressed genes following the combination treatment, compared to p53Null cells, although the combination treatment regulated individual pathways in the different cell lines. APR-246 mediated radio-sensitization effects through p53-dependent and -independent ways.

2023-05-12 | GSE232305 | GEO

Influenza virus facilitates its infectivity by activating p53 to inhibit the expression of interferon-induced transmembrane proteins (IFITMs)

Project description:Transcriptome analysis of mock or H1N1 IAV PR8 infected p53WT A549 and p53null A549-KO3 cells by Affymetrix GeneChip Human Transcriptome 2.0 Arrays to achieve a set of genes those are regulated by p53 and responsive to IAV infection. Influenza A virus infection activates cellular p53, however it has not been clear whether this process has pro- or anti- viral effects. In this study, using human isogenic p53 wildtype A549 cells and p53null A549-KO3 cells generated from the CRISPR/Cas9 technology, we report that p53null cells exhibit significantly reduced viral propagation property when infected with influenza A virus (H1N1/A/Puerto Rico/8/34). Here, using genome-wide microarray analysis we revealed that p53 regulates the expression of a large set of interferon-inducible genes, some of which are directly associated with viral infectivity and later experimentally validated to be responsible for p53-regulated IAV infectivity.

2018-05-31 | GSE106279 | GEO

Transcriptomic analysis of two human non-small-cell lung cancer cell lines in response to SN1 methylating-agents treatment

Project description:Methylating agents of SN1 type constitute a widely used class of anticancer drugs, the effect of which on human non-small-cell lung cancer (NSCLC) has not been adequately studied. We thus studied the effect of N-methyl-N-nitrosourea (MNU), a model SN1 methylating agent, on two human NSCLC cell lines: A549 (p53wt) and H157 (p53null). We investigated the mechanism of MNU-induced cell death through a time course gene expression profiling study, 24, 48 and 72h following treatment. Two human NSCLC cell lines (A549, H157) were treated with MNU or DMSO for 24h, 48h, or 72h. 34 total samples were analyzed.

2016-06-30 | E-GEOD-65933 | biostudies-arrayexpress

Transcriptomic analysis of two human non-small-cell lung cancer cell lines in response to SN1 methylating-agents treatment

2016-06-30 | GSE65933 | GEO

Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo

Project description:Chromosomal translocations affecting Mixed Lineage Leukemia (MLL) gene result in acute leukemias resistant to therapy. The leukemogenic activity of MLL fusion proteins is dependent on their interaction with menin, providing basis for therapeutic intervention. Here we report development of novel, highly potent and orally bioavailable small molecule inhibitors of the menin-MLL interaction, MI-463 and MI-503, show their profound effects in MLL leukemia cells and substantial survival benefit in mice models of MLL leukemia. Finally, we demonstrate efficacy of these compounds in primary samples derived from MLL leukemia patients. Overall, we demonstrate for the first time that pharmacologic inhibition of the menin-MLL interaction represents an effective treatment for MLL leukemias in vivo and provide advanced molecular scaffold for clinical lead identification.

2017-08-21 | GSE60673 | GEO

A Novel Inducible Mouse Model of MLL-ENL-driven Mixed-lineage Acute Leukemia.

Project description: Not available

| S-EPMC6745998 | biostudies-literature

Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.

Project description: Not available

| S-EPMC5351781 | biostudies-other